Analysis of cytokine profile in human colonic mucosal Fc epsilonRI-positive cells by single cell PCR: inhibition of IL-3 expression in steroid-treated IBD patients.
Mast cells can serve as a possible important source of cytokine production in inflamed tissue which can be regulated by stimuli different from those activating other immune system cells. To study the expression of specific genes in mast cells derived from small human colonic mucosal endoscopic biopsies, we first modified a previously reported procedure to achieve a significantly enriched mast cell fraction. Then, by using single-cell RT-PCR analysis the expression of the IgE Fc receptor (Fc epsilonRI) and c-kit mRNA was determined. It was observed that the Fc epsilonRI-positive cells also expressed c-kit. This observation provided further evidence that Fc epsilonRI-positive cells are indeed mast cells. Analysis of biopsies from 12 patients (four control and eight patients with inflammatory bowel disease (IBD)) was carried out, revealing that all of the Fc epsilonRI-positive cells expressed IL-3, while the expression of IL-4 was detected only in some of these positive cells. TNF alpha was not detected in these cells. Therefore, it would seem that most intestinal mast cells produce IL-3. Since it has been reported that IL-3 synthesis was down-regulated in steroid-treated cells, the expression pattern of IL-3 in intestinal mast cells derived from steroid-treated IBD patients was then determined. IL-3 mRNA was detected in only two out of 24 Fc epsilonRI-positive cells derived from these steroid-treated patients. These results lend strong support to the idea that the down-regulation of IL-3 in mast cells derived from steroid-treated IBD patients occurs in vivo and could be an important mechanism for immunomodulation in IBD.
Ligumsky
M
M
Division of Internal Medicine, Hadassah Medical Center, Jerusalem, Israel.
Kuperstein
V
V
Nechushtan
H
H
Zhang
Z
Z
Razin
E
E
D001706:Biopsy; D002478:Cells, Cultured; D003106:Colon / Q000166:cytology / Q000276:immunology / Q000473:pathology; D017931:DNA Primers; D005786:Gene Expression Regulation / Q000187:drug effects; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D007377:Interleukin-3 / Q000096:biosynthesis*; D015847:Interleukin-4 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis; D007378:Interleukins / Q000096:biosynthesis*; D007413:Intestinal Mucosa / Q000166:cytology / Q000276:immunology* / Q000473:pathology; D008407:Mast Cells / Q000166:cytology / Q000276:immunology* / Q000473:pathology; D015345:Oligonucleotide Probes; D016133:Polymerase Chain Reaction / Q000379:methods; D017455:Receptors, IgE / Q000032:analysis / Q000096:biosynthesis*; D012016:Reference Values; D014158:Transcription, Genetic / Q000187:drug effects*
D017931:DNA Primers; D005938:Glucocorticoids; D007377:Interleukin-3; D016209:Interleukin-8; D007378:Interleukins; D015345:Oligonucleotide Probes; D017455:Receptors, IgE; D015847:Interleukin-4